Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This pharmacological decolonization treatment is a multi-component antimicrobial regimen evaluated in a randomized controlled study (NCT00966446) led by Joseph Kim. The regimen is designed to eliminate methicillin-resistant Staphylococcus aureus (MRSA) carriage in community outpatients. It consists of a three-pronged approach: topical decolonization using chlorhexidine gluconate (4% body scrub and 2% shampoo daily), intranasal decolonization using mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% twice daily, and systemic oral antibiotics using either trimethoprim-sulfamethoxazole (160/800mg) or doxycycline (100mg) twice daily for a duration of seven days. The strategy aims to reduce the reservoir of MRSA on the skin, in the nares, and systemically to prevent recurrent infections and transmission in the community setting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pharmacological decolonization treatment.